BACKGROUND: Previous studies suggest that recurrent episodes of coughing and wheezing occur in up to 75% of @entity1 after @entity25081 . AIM: To assess the efficacy of @entity4184 given by means of a metered dose inhaler, spacer, and face mask in reducing the incidence of coughing and wheezing episodes up to 12 months after @entity25081 . METHODS: @entity1 under the age of 12 months admitted to hospital with @entity25081 were randomised to receive either @entity4184 or placebo (200 microg or one puff twice daily) for the next eight weeks. Parents kept a diary card record of all episodes of coughing and wheezing over the next 12 months. RESULTS: Full follow up data were collected for 49 @entity1 . There were no significant differences between the two study groups for the number of @entity1 with symptom episodes up to six months after hospital discharge. At 12 months, 21 @entity1 in the @entity4184 group had symptom episodes compared with 12 of 24 in the placebo group. The median number of symptom episodes was 2 (range, 0-13) in those who received @entity4184 and 1 (range, 0-11) in those who received placebo. Because there is no pharmacological explanation for these results, they are likely to be caused by a type 1 error, possibly exacerbated by there being more @entity1 in the treatment group. CONCLUSION: Routine administration of @entity4184 by means of a metered dose inhaler, spacer, and face mask system immediately after @entity25081 cannot be recommended.

Randomised controlled trial of XXXX for the prevention of post-bronchiolitis wheezing.

@entity1 :: ('9606', 'Species') :: ['Children', 'boys', 'infants'] @entity25081 :: ('MESH:D001990', 'Disease') :: ['acute viral bronchiolitis'] @entity4184 :: ('MESH:D019819', 'Chemical') :: ['budesonide']
@entity4184 :: (MESH:D019819,Chemical) :: ['budesonide']
